Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AMLX Amylyx Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AMLX
Price (delayed)
$4.35
Market cap
$387.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.1
Enterprise value
$327.93M
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a
Highlights
The quick ratio has soared by 167% YoY and by 83% from the previous quarter
Amylyx Pharmaceuticals's debt has plunged by 63% YoY and by 30% from the previous quarter
AMLX's EPS has dropped by 198% year-on-year but it is up by 30% since the previous quarter
AMLX's gross profit has dropped by 104% year-on-year but it has surged by 75% since the previous quarter
Amylyx Pharmaceuticals's revenue has plunged by 101% from the previous quarter and by 100% YoY
Key stats
What are the main financial stats of AMLX
Market
Valuations
Earnings
Shares outstanding
89.14M
Market cap
$387.76M
Enterprise value
$327.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
-$1.27M
Gross profit
-$9.5M
Operating income
-$230.4M
Net income
-$218.86M
EBIT
-$219.49M
EBITDA
-$218.75M
Free cash flow
-$207.08M
Per share
Balance sheet
Liquidity
EPS
-$3.1
EPS diluted
-$3.1
Free cash flow per share
-$2.42
Book value per share
$2.27
Revenue per share
-$0.01
TBVPS
$2.56
Total assets
$219.68M
Total liabilities
$18.26M
Debt
$1.38M
Equity
$201.42M
Working capital
$198.21M
Debt to equity
0.01
Current ratio
12.05
Quick ratio
11.48
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-87.9%
Return on equity
-106.3%
Return on invested capital
-160.8%
Return on capital employed
-108.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMLX stock price
How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
-3.12%
1 week
-10.68%
1 month
11.54%
1 year
132.62%
YTD
15.08%
QTD
22.88%
Financial performance
How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
-$1.27M
Gross profit
-$9.5M
Operating income
-$230.4M
Net income
-$218.86M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 183% YoY but it rose by 27% QoQ
AMLX's gross profit has dropped by 104% year-on-year but it has surged by 75% since the previous quarter
Amylyx Pharmaceuticals's revenue has plunged by 101% from the previous quarter and by 100% YoY
Amylyx Pharmaceuticals's net income has increased by 27% QoQ
Price vs fundamentals
How does AMLX's price correlate with its fundamentals
Growth
What is Amylyx Pharmaceuticals's growth rate over time
Valuation
What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AMLX's EPS has dropped by 198% year-on-year but it is up by 30% since the previous quarter
AMLX's P/B is 59% above its last 4 quarters average of 1.2
The equity has declined by 38% year-on-year but it rose by 22% since the previous quarter
Amylyx Pharmaceuticals's revenue has plunged by 101% from the previous quarter and by 100% YoY
Efficiency
How efficient is Amylyx Pharmaceuticals business performance
The company's return on invested capital rose by 25% QoQ
Amylyx Pharmaceuticals's ROE has increased by 17% from the previous quarter
Amylyx Pharmaceuticals's ROA has increased by 13% from the previous quarter
Dividends
What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMLX.
Financial health
How did Amylyx Pharmaceuticals financials performed over time
The current ratio has soared by 169% year-on-year and by 81% since the previous quarter
The quick ratio has soared by 167% YoY and by 83% from the previous quarter
Amylyx Pharmaceuticals's debt is 99% less than its equity
Amylyx Pharmaceuticals's debt has plunged by 63% YoY and by 30% from the previous quarter
The equity has declined by 38% year-on-year but it rose by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.